![]() |
Home / Employment / Contact / Search / Français / Español |
||
![]() |
|
Prevention of MTCT: Interventions UNICEF's activities to control the HIV/AIDS epidemic Recent research has shown that a range of interventions can reduce the risk of mother to child transmission of HIV/AIDS by up to 50 per cent. The primary effort is being directed to trying to prevent HIV/AIDS infection in women, young women in particular. In addition, three key interventions are being used to help to prevent mother to child transmission of HIV:
Antiretroviral Drugs Antiretroviral drugs reduce mother to child transmission when started before, during delivery, but even if taken within 48 hours after delivery. Antiretrovirals work mainly through two mechanisms:
Risk reduction through antiretroviral therapy given in the antenatal period and during delivery persists through the breastfeeding period. Continuing antiretrovirals in breastfed children is a promising new intervention likely to be effective in reducing transmission of HIV through breastmilk. Although some side effects have been observed, antiretrovirals are generally safe with the benefits of the drugs outweigh the risk of side effects. These drugs continue to be monitored. UNICEF-assisted MTCT prevention programmes use the drug AZT (sometimes called zidovudine or ZDV) and have adopted the protocol initially developed in Thailand in 1997. This short regimen gave 300 mg AZT orally twice daily from 36 weeks gestation until the onset of labour and 300 mg every three hours from the onset of labour until delivery. This regimen decreased mother to child HIV-1 transmission by 37-38 per cent in breastfeeding populations after 18 months and by 50 per cent in non-breastfeeding populations. Botswana used a modified regimen of antiretroviral therapy at 34 weeks and administered AZT syrup to the baby for four weeks. In January 1999, the results of a major research study in Uganda became available which showed that another drug, nevirapine, could achieve an equivalent reduction of transmission with only a single dose to the mother during labour and a single dose to the baby within three days of birth. The nevirapine regimen costs about $4.00 for each mother /child pair. The current consensus of the UN agencies is that nevirapine is one of the suitable regimens for decreasing the risk of MTCT of HIV/AIDS, especially for women who detect their HIV positive status or arrive at the health facility too late in the pregnancy to benefit from the AZT regimen. The new single dose nevirapine regimen substantially lowers the cost barrier that has kept many countries from adopting drug strategies to prevent perinatal transmission. Long term follow-up of both the mothers and babies remains a high priority to assess any late drug toxicities as well as long term survival. Research results may indicate that a combination of nevirapine with AZT or other drugs may be more effective. Findings will have important implications for the provision of interventions to prevent MTCT of HIV in developing countries. Both AZT and nevirapine are on the WHO List of Essential Drugs for MTCT. The low cost of nevirapine does not, however, justify mass treatment without individual counselling and testing. The side effects of nevirapine have not been fully established yet. Additionally, blanketing populations with this drug can create resistance to it
Since there is a possibility of transmitting HIV through breastfeeding, replacement feeding is an option for mothers. If an HIV-infected mother has access to an adequate supply of breastmilk substitutes, knows how to use them, has access to fuel and clean water and the time to prepare breastmilk substitutes safely, refraining from breastfeeding will reduce the risk of transmitting HIV through breastfeeding. In countries where families live in poverty, have limited education and poor access to the resources required to provide safe feeding alternatives to breastfeeding, including counselling, however, the risk of death from diarrhoea, respiratory, and other infections associated with replacement feeding can be as great or greater than the risk of transmitting HIV through breastfeeding. As a general principle, the guidelines advocate that in all populations, irrespective of HIV infection rates, breastfeeding should be protected, promoted and supported and that HIV positive mothers who choose to breastfeed should be given full support for their decisions. Women who do not wish to be tested for HIV and those who have tested negative should be encouraged to breastfeed. If an HIV positive mother chooses to breastfeed, she should do so exclusively. Combining breastfeeding and replacement feeding is inadvisable because partial breastfeeding supplemented with water, formula or other drinks appears to elevate health risks, including HIV transmission, possibly because these supplements can damage the infant's gut and make it easier for viruses to cross the intestinal mucosa. The consensus of ongoing research to determine mechanisms of HIV transmission from an infected mother to her child is that the risk of transmission will be reduced if the duration of breastfeeding is limited. The exclusively breastfeeding mother, therefore, may wish to stop breastfeeding completely at 4 to 6 months to prevent late postnatal MTCT. However, at the present time, the evidence is not strong enough to make a firm recommendation on a specific cut-off age when breastfeeding should completely stop. Recommendations will be kept under review as knowledge in this area increases.
|
||||||||||
|
|